Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021 ... 11 May, 2021
Oculis to Present Recent Progress in its Portfolio at Upcoming Investor Conferences 24 November, 2020
Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech 10 September, 2020
Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer 01 September, 2020
